share_log

Financial Survey: Avalon GloboCare (ALBT) Vs. Its Rivals

Defense World ·  Jan 27, 2023 01:19

Avalon GloboCare (NASDAQ:ALBT – Get Rating) is one of 60 public companies in the "Management consulting services" industry, but how does it weigh in compared to its competitors? We will compare Avalon GloboCare to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Avalon GloboCare and its competitors, as provided by MarketBeat.com.

Get Avalon GloboCare alerts:
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalon GloboCare 0 0 0 0 N/A
Avalon GloboCare Competitors 54 447 965 15 2.64

As a group, "Management consulting services" companies have a potential upside of 45.39%. Given Avalon GloboCare's competitors higher probable upside, analysts plainly believe Avalon GloboCare has less favorable growth aspects than its competitors.

Volatility & Risk

Avalon GloboCare has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Avalon GloboCare's competitors have a beta of 1.76, indicating that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Avalon GloboCare and its competitors' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Avalon GloboCare -955.48% -460.58% -97.43%
Avalon GloboCare Competitors -56.87% -79.82% -7.02%

Valuation & Earnings

This table compares Avalon GloboCare and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Avalon GloboCare $1.39 million -$9.09 million -2.59
Avalon GloboCare Competitors $1.54 billion $108.11 million 13.68

Avalon GloboCare's competitors have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

0.9% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 41.3% of shares of all "Management consulting services" companies are owned by institutional investors. 64.0% of Avalon GloboCare shares are owned by insiders. Comparatively, 29.2% of shares of all "Management consulting services" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Avalon GloboCare competitors beat Avalon GloboCare on 9 of the 10 factors compared.

Avalon GloboCare Company Profile

(Get Rating)

Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.

Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment